Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of allogeneic umbilical cord-derived mesenchymal cells for severe COVID-19 pulmonary involvement
2020-001450-22Phase 2Terminated
- Sponsor
- Fundación para la Investigación Biomédica Hospital Universitario Niño Jesús
- Start
- May 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, single-arm trial of allogeneic umbilical cord-derived mesenchymal stem cells in coronavirus disease 2019 (COVID-19), sponsored by Fundación para la Investigación Biomédica Hospital Universitario Niño Jesús. Primary endpoint: Mortality due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment. Started May 2020; status: terminated.
02
Drugs
allogeneic umbilical cord-derived mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001450-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001450-22.